AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10396166 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 75
Study 10396166 — intervention group
Group type: COMPARATOR
Intervention: Outpatient-based rehabilitation
Number of subjects: 75
Study 7568623 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal caffeine consumption
Number of subjects: 25
Study 7568623 — intervention group
Group type: COMPARATOR
Intervention: Caffeine deprivation
Number of subjects: 25
Study 2285683 — intervention group
Group type: EXPERIMENTAL
Intervention: levobunolol 0.5%
Number of subjects: 25
Study 2285683 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 7018438 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 0
Study 7018438 — intervention group
Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 0
Study 31192699 — intervention group
Group type: EXPERIMENTAL
Intervention: Caressing (hugging)
Number of subjects: 120
Study 31192699 — intervention group
Group type: COMPARATOR
Intervention: Control (no caressing)
Number of subjects: 120
Study 31462110 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiofrequency ablation (SRFA)
Number of subjects: 79
Study 31462110 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-subcardiac HCC)
Number of subjects: 79
Study 28228425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (8 g oligofructose-enriched inulin/d)
Number of subjects: 42
Study 28228425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 42
Study 26027222 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 88
Study 26027222 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 88
Study 24166792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 387
Study 24166792 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline levels of erythrocyte folate
Number of subjects: 387
Study 24166792 — intervention group
Group type: EXPERIMENTAL
Intervention: Other one-carbon metabolism biomarkers
Number of subjects: 387
Study 24166792 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of biomarkers and changes after 3 months
Number of subjects: 387
Study 22060248 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (10-week web-based treatment with weekly therapist support via e-mail)
Number of subjects: 76
Study 22060248 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided self-help (10-week web-based treatment without therapist support)
Number of subjects: 76
Study 22060248 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 76
Study 19082528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (calcium supplement plus menatetrenone)
Number of subjects: 4378
Study 19082528 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (calcium supplement)
Number of subjects: 4378
Study 18251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg every four hours for 48 hours)
Number of subjects: 49
Study 18251131 — intervention group
Group type: COMPARATOR
Intervention: Albumin (8g/L of removed ascites)
Number of subjects: 49
Study 18251131 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 49
Study 18251131 — intervention group
Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 49
Study 14679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 371
Study 14679443 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam/amoxicillin-clavulanate
Number of subjects: 371
Study 14679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (specifically for infected foot ulcers)
Number of subjects: 371
Study 14679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (specifically for patients without osteomyelitis)
Number of subjects: 371
Study 14679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and comparators (inpatients and outpatients)
Number of subjects: 371
Study 14679443 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and comparators (oral and intravenous formulations)
Number of subjects: 371
Study 12055663 — intervention group
Group type: EXPERIMENTAL
Intervention: STW 5
Number of subjects: 186
Study 12055663 — intervention group
Group type: EXPERIMENTAL
Intervention: STW 5-II
Number of subjects: 186
Study 12055663 — intervention group
Group type: COMPARATOR
Intervention: cisapride
Number of subjects: 186
Study 9931791 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of parathyroid glands during surgery
Number of subjects: 579
Study 9931791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral conventional subtotal resection
Number of subjects: 579
Study 9931791 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of the operation and manipulation of the parathyroid glands
Number of subjects: 579
Study 7646919 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)
Number of subjects: 59
Study 7646919 — intervention group
Group type: COMPARATOR
Intervention: CNOP (cyclophosphamide, mitoxantrone, vincristine and prednisolone)
Number of subjects: 59
Study 7646919 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 59
Study 7646919 — intervention group
Group type: COMPARATOR
Intervention: CNOP
Number of subjects: 59
Study 2692971 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenticonazole (2%) spray
Number of subjects: 100
Study 2692971 — intervention group
Group type: COMPARATOR
Intervention: Naftifine (1%) spray
Number of subjects: 100
Study 413345 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanozolol
Number of subjects: 0
Study 413345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30561672 — intervention group
Group type: COMPARATOR
Intervention: rVSVDG-ZEBOV-GP vaccine
Number of subjects: 210
Study 28029409 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg/day) for 30 days
Number of subjects: 48
Study 28029409 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (1000 cal/day) for 30 days
Number of subjects: 48
Study 28029409 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 48
Study 25995585 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain rehabilitation program + treadmill exercise (30 min, 3.0-3.5 km/h, thrice/week for 8 weeks)
Number of subjects: 20
Study 25995585 — intervention group
Group type: COMPARATOR
Intervention: Low back pain rehabilitation program (30 min, thrice/week for 8 weeks)
Number of subjects: 20
Study 23413415 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 92
Study 23413415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 23413415 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 92
Study 21272399 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g whey protein isolate
Number of subjects: 20
Study 21272399 — intervention group
Group type: COMPARATOR
Intervention: 45 g sodium caseinate
Number of subjects: 20
Study 21272399 — intervention group
Group type: COMPARATOR
Intervention: 45 g glucose control
Number of subjects: 20
Study 19581618 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared access to a Web-based, colour-coded diabetes tracker providing monitoring values for 13 diabetes risk factors
Number of subjects: 511
Study 19581618 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared access to a Web-based, colour-coded diabetes tracker
Number of subjects: 511
Study 19581618 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 511
Study 16251993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 20
Study 16251993 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg (placebo)
Number of subjects: 20
Study 15332386 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC) combination (50/500 microg)
Number of subjects: 6200
Study 15332386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg)
Number of subjects: 6200
Study 15332386 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 6200
Study 15332386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6200
Study 15332386 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC, fluticasone propionate, salmeterol, placebo
Number of subjects: 6200
Study 11164668 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical silver sulfadiazine combined with cerium nitrate (SSD‐CN)
Number of subjects: 60
Study 11164668 — intervention group
Group type: COMPARATOR
Intervention: Topical silver sulfadiazine (SSD)
Number of subjects: 60
Study 9266790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole infusion (0.56 mg/kg over a 4‐minute period) 48 to 96 hours after onset of symptoms
Number of subjects: 284
Study 9266790 — intervention group
Group type: COMPARATOR
Intervention: Control group (no test)
Number of subjects: 284
Study 8492964 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxicam (20 mg/day, orally administered)
Number of subjects: 0
Study 8492964 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam (20 mg/day, orally administered)
Number of subjects: 0
Study 2893634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 31-1118
Number of subjects: 8
Study 2893634 — intervention group
Group type: EXPERIMENTAL
Intervention: Flusoxolol
Number of subjects: 8
Study 2893634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 8
Study 2893634 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 8
Study 2893634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 8
Study 2893634 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study 2893634 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8
Study 2893634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30143316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block with up to 20mL of 0.3mL.kg‐1 of 0.5% bupivacaine and intravenous tramadol
Number of subjects: 32
Study 30143316 — intervention group
Group type: COMPARATOR
Intervention: Standard management group; up to 3mL of 0.9% saline in the femoral sheath and intravenous tramadol
Number of subjects: 32
Study 27026442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of Restor +2.5 D multifocal IOLs
Number of subjects: 103
Study 27026442 — intervention group
Group type: COMPARATOR
Intervention: Contralateral implantation of Restor +2.5 D IOL in dominant eye and Restor +3.0 D IOL in fellow eye
Number of subjects: 103
Study 25453990 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-Hz rTMS
Number of subjects: 18
Study 25453990 — intervention group
Group type: COMPARATOR
Intervention: 1-Hz rTMS
Number of subjects: 18
Study 25453990 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 20-Hz rTMS and 1-Hz rTMS
Number of subjects: 18
Study 23739902 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercise (60 min, three times per week for 12 weeks)
Number of subjects: 40
Study 23739902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study 20593142 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) supplementation during CABG surgery
Number of subjects: 92
Study 20593142 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administered just before the release of the aortic cross clamp
Number of subjects: 92
Study 20593142 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Mg supplementation)
Number of subjects: 92
Study 20593142 — intervention group
Group type: COMPARATOR
Intervention: NAC untreated group (placebo with dextrose solution)
Number of subjects: 92
Study 18703812 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (in SPORTIF V)
Number of subjects: 0
Study 18703812 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (in SPORTIF III)
Number of subjects: 0
Study 18703812 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing stroke risk in SPORTIF V
Number of subjects: 0
Study 15691565 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone optic IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: Acrylic optic IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: Round-edge optic IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: Sharp-edge optic IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: PMMA loop IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: Polyvinylidene fluoride loop IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: Single-piece acrylic haptic IOL
Number of subjects: 331
Study 15691565 — intervention group
Group type: COMPARATOR
Intervention: 3-piece PMMA haptic IOL
Number of subjects: 331
Study 12829674 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/d of PTX and 1,000 U/d of Vit E
Number of subjects: 24
Study 12829674 — intervention group
Group type: COMPARATOR
Intervention: PTX plus placebo
Number of subjects: 24
Study 12829674 — intervention group
Group type: COMPARATOR
Intervention: placebo plus Vit E
Number of subjects: 24
Study 12829674 — intervention group
Group type: COMPARATOR
Intervention: placebo-placebo
Number of subjects: 24
Study 11013551 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Analysis training
Number of subjects: 40
Study 11013551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 40
Study 8928439 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared (lambda = 0.85 microns) laser radiation to the skin
Number of subjects: 0
Study 1739193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 0
Study 1739193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 0
Study 1739193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and diltiazem
Number of subjects: 0
Study 1739193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1739193 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 0
Study 6734709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive steroids
Number of subjects: 20
Study 6734709 — intervention group
Group type: COMPARATOR
Intervention: Control (no oral contraceptive steroids)
Number of subjects: 20
Study 30161180 — intervention group
Group type: EXPERIMENTAL
Intervention: LED light set to 5000K (higher CCT)
Number of subjects: 20
Study 30161180 — intervention group
Group type: COMPARATOR
Intervention: LED light set to 3500K (lower CCT)
Number of subjects: 20
Study 26910661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid injection
Number of subjects: 25
Study 23796208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention including staff training and written breastfeeding procedure
Number of subjects: 110
Study 23796208 — intervention group
Group type: COMPARATOR
Intervention: Historical group (no intervention)
Number of subjects: 110
Study 23796208 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 110
Study 23796208 — intervention group
Group type: EXPERIMENTAL
Intervention: Having at least one stress factor during pregnancy
Number of subjects: 110
Study 22135154 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics (cefazolin 1 g given <30 minutes prior to skin incision)
Number of subjects: 434
Study 22135154 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative antibiotics (cefazolin 1 g at cord clamping)
Number of subjects: 434
Study 22135154 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics or intraoperative antibiotics
Number of subjects: 434
Study 20194915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (600 mg/d after titration over 8 weeks)
Number of subjects: 32
Study 20194915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20194915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 32
Study 18538052 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary flow rate (10 mL kg(‐1) h(‐1))
Number of subjects: 24
Study 18538052 — intervention group
Group type: COMPARATOR
Intervention: Low urinary flow rate (3 mL kg(‐1) h(‐1))
Number of subjects: 24
Study 16041725 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE)
Number of subjects: 15
Study 16041725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 12801492 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 12801492 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 60
Study 12801492 — intervention group
Group type: COMPARATOR
Intervention: Normal GP care (Control)
Number of subjects: 60
Study 10857818 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-surface-modified (HSM) intraocular lenses
Number of subjects: 367
Study 8853141 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated guidewires with blood exposure for 3 minutes
Number of subjects: 35
Study 8853141 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated guidewires with blood exposure for 5 minutes
Number of subjects: 35
Study 8853141 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated guidewires with blood exposure for 10 minutes
Number of subjects: 35
Study 8853141 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose systemic administration of heparin (2,500 units)
Number of subjects: 35
Study 1642831 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily radiation plus concomitant chemotherapy with cisplatin and fluorouracil (5-fluorouracil)
Number of subjects: 58
Study 1642831 — intervention group
Group type: COMPARATOR
Intervention: Twice daily radiation alone
Number of subjects: 58
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 75
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 75
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg
Number of subjects: 75
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (ASA) 500 mg
Number of subjects: 75
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (ASA) 1500 mg
Number of subjects: 75
Study 6384073 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 75
Study 31985173 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with a male doctor
Number of subjects: 153
Study 31985173 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with a female doctor
Number of subjects: 153
Study 30993748 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab (combined treatment groups from two phase 2b trials)
Number of subjects: 475
Study 30407329 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E
Number of subjects: 240
Study 30407329 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 240
Study 26275544 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 81
Study 26275544 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 81
Study 25225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel traction group (B)
Number of subjects: 216
Study 25225464 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (C)
Number of subjects: 216
Study 25225464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventroflexion traction group (A)
Number of subjects: 216
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.09 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.21 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg biotin/kg
Number of subjects: 576
Study 23281759 — intervention group
Group type: COMPARATOR
Intervention: 0 mg biotin/kg (control)
Number of subjects: 576
Study 20731476 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine ER (1-4 mg once daily)
Number of subjects: 0
Study 20731476 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine ER (1-4 mg/day)
Number of subjects: 0
Study 17035721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (100 mg/day)
Number of subjects: 42
Study 17035721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream
Number of subjects: 42
Study 17035721 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lotion
Number of subjects: 42
Study 17035721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement + topical formulations
Number of subjects: 42
Study 17035721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplement)
Number of subjects: 42
Study 11203862 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched with H3PO4 for 15 seconds
Number of subjects: 10
Study 11203862 — intervention group
Group type: COMPARATOR
Intervention: Etched with H3PO4 for 15 seconds followed by collagen removal with 5% NaOCl for two minutes
Number of subjects: 10